MedPath

Real Risks of the Online World

Not Applicable
Completed
Conditions
Sexual Health
Registration Number
NCT04714034
Lead Sponsor
University of Zurich
Brief Summary

Development and validation of questionnaire/scale to assess problematic online dating app (ODA) use in a sub-cohort of the SwissPrEPared cohort study (validation sample: n=229). Longitudinal design to assess the association of problematic ODA use and sexual/mental health and substance use outcomes. No randomised trial, only 1 cohort which will be stratified according to severity/risk of problematic ODA use.

Detailed Description

This project may fill an important gap of knowledge in a research area that has taken on major importance over the past few years, and has thus the potential to impact several major public health recommendations. First, considering the high penetrance of dating apps in the men who have sex with men (MSM) population (reaching 78.2% in a recent report), more than 62,000 MSM in Switzerland are estimated to use such applications. How many of them suffer from addiction or problmatic use remains unclear and our project will be the first to provide estimates of the prevalence of problematic ODA use in this particular population. Second, our project will help to clarify the impact of online dating app usage on health outcomes. By identifying drivers of the current HIV/(sexual transmitted infections (STI) epidemic in Switzerland, our project might thus provide critical information to shape future prevention measures aiming at further reducing HIV/STI incidence rates. Third, because sexual risk-taking increases with substance use and depression, it remains crucial to detect mental health outcomes early and provide adequate care to populations at high risk of HIV, or other STI, transmission. Fourth, our study might identify a new phenomenon related to high-risk sexual behaviour that may not be limited to the MSM group, but could also affect other, larger populations interacting and meeting through online communication channels. Considering that more than 41 million people are currently using dating apps in Europe, our findings might have a substantial impact on the general population. Finally, this project might provide the very first insights on the interplay between online dating, substance use, mental health and sexual risk taking. This new understanding could then help Switzerland create additional measures for preventing HIV transmission and reach the UNAIDS targets for HIV elimination by 2030.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
229
Inclusion Criteria
  • currently engaging in online dating (i.e., using applications/websites with the aim to meet potential relationship or sexual partners or having used them actively in the past 12 months)
  • Participating in the SwissPrEPared study at center Checkpoint Zurich
  • German speaking
Exclusion Criteria
  • Potential participants will be excluded if they are unable to follow study procedures.

For Inclusion/Exclusion at the SwissPrEPared study see: NCT03893188 at clinicaltrials.gov

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Develop and validate a scale measuring problematic online dating app (ODA) usesingle measurement (one day per participant)

Scale development and validation will follow the FDA guidance for patient-reported outcomes and recommendations on questionnaire research. Preliminary testing, pilot-testing, and validation will be conducted in participants from the SwissPrEPared Study

Associated mental, sexual health and substance use outcomes of problematic ODA use6 months

Evaluate the association of problematic ODA use with:

Sexual health outcomes (incident cases of STI, such as syphilis, gonorrhoea and chlamydia, or HIV), over 6 months Mental health outcomes: prevalence of psychiatric disorders, measured at baseline and 12 months, using validated questionnaires Substance use outcomes: Lifetime, 12-month, 3-month prevalence and frequency rates

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Epidemiology, Biostatistics and Prevention Institute

🇨🇭

Zürich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath